机构名称：
¥ 1.0
肺部和北美的肺化分枝杆菌（NTM）的患病率正在增加。大多数肺NTM是由鸟分枝杆菌（MAC）引起的。肺MAC的治疗是次优的，失败率范围从30％到40％，需要开发新的疫苗。在这项研究中，我们测试了两种全细胞疫苗，DAR-901（HEAD杀死M. Obuense）和BCG（Live Pive nive nive s. Bovis），通过首先对Balb/C小鼠进行免疫接种，然后进行过夜刺激过夜刺激，从而诱导MAC交叉反应免疫。研究这些疫苗预防MAC感染的能力，BALB/C小鼠以DAR-901（皮内）或BCG（皮下或鼻内内）接种疫苗，并在4周后用雾化的MAC挑战。一些通过饲料用克拉霉素治疗了接受BCG接种的小鼠。感染后4周对免疫小鼠和未接种疫苗的对照进行肺CFU。 Our results showed that i) DAR-901 induced cross-reactive immunity to MAC and the level of MAC cross-reactive immunity was similar to the level of immunity induced by BCG, ii) DAR-901 and BCG protect against aerosol MAC, iii) mucosal BCG vaccination provided the best protection against MAC challenge, and iv) BCG vaccination did not interfere with anti-MAC activities of克拉霉素。肺CFU。Our results showed that i) DAR-901 induced cross-reactive immunity to MAC and the level of MAC cross-reactive immunity was similar to the level of immunity induced by BCG, ii) DAR-901 and BCG protect against aerosol MAC, iii) mucosal BCG vaccination provided the best protection against MAC challenge, and iv) BCG vaccination did not interfere with anti-MAC activities of克拉霉素。
免疫对由dar-诱导的鸟分枝杆菌的免疫力
主要关键词
相关文件推荐
